Background Dr. Athina Markou sought treatments for a common neural substrate shared by depression and drug dependence. Antagonists of corticotropin-releasing factor (CRF) receptors, a target of interest to her, have not reached the clinic despite strong preclinical rationale and sustained translational efforts. Methods We explore potential causes for the failure of CRF 1 antagonists and review recent findings concerning CRF-CRF 1 systems in psychopathology. Results Potential causes for negative outcomes include (1) poor safety and efficacy of initial drug candidates due to bad pharmacokinetic and physicochemical properties, (2) specificity problems with preclinical screens, (3) the acute nature of screens vs. late-presenting patients, (4) positive preclinical results limited to certain models and conditions with dynamic CRF-CRF 1 activation not homologous to tested patients, (5) repeated CRF 1 activation-induced plasticity that reduces the importance of ongoing CRF 1 agonist stimulation, and (6) therapeutic silencing which may need to address CRF 2 receptor or CRF-binding protein molecules, constitutive CRF 1 activity, or molecules that influence agonist-independent activity or to target structural regions other than the allosteric site bound by all drug candidates. We describe potential markers of activation towards individualized treatment, human genetic, and functional data that still implicate CRF 1 systems in emotional disturbance, sex differences, and suggestive clinical findings for CRF 1 antagonists in food craving and CRF-driven HPAaxis overactivation. Conclusion The therapeutic scope of selective CRF 1 antagonists now appears narrower than had been hoped. Yet, much remains to be learned about CRF's role in the neurobiology of dysphoria and addiction and the potential for novel anti-CRF therapies therein.
In an early, influential contribution, Dr. Athina Markou, with Drs. Kosten and Koob, cited comorbidity data, preclinical findings on the neurobiological consequences of substances of abuse, and similar neurotransmitter alterations to propose that drug dependence and major depression share a common neurobiological substrate. In this conceptual model, drug use is motivated by negative reinforcement mechanisms to relieve depression-like symptoms-the so-called Bself-medicationĥ ypothesis (Markou et al. 1998; . From that time on, a thrust of research in their and other laboratories has been to identify novel compounds with antidepressant and anxiolytic activity (Markou and Cryan 2012) in order to reduce the suffering of emotional disorders and the abstinent state in drug-dependent individuals. Relatedly, novel compounds (e.g., metabotropic glutamate receptor 5 antagonists; Markou 2007; Stoker et al. 2012 ) and recognized antidepressants, such as fluoxetine, bupropion, and desipramine (Lin et al. 1999; Cryan et al. 2003a; Bruijnzeel and Markou 2003; Takamatsu et al. 2006 Takamatsu et al. , 2011 Paterson et al. 2008a Paterson et al. , b, 2007 , have been used as pharmacological tools to better understand the neurobiology of drug dependence.
At the same time that the shared neurobiology and selfmedication hypothesis was published, there was mounting interest in the therapeutic potential of corticotropin-releasing factor (CRF) receptor antagonists to treat stress-related psychiatric disorders. Preclinical studies during the previous 15 years had strongly supported the hypothesis that CRF was a key physiological mediator of not only neuroendocrine responses but also behavioral responses to psychosocial stress, and stress was a known etiologic factor in depression, anxiety disorders, and addiction. The cloning of a second CRF receptor subtype in 1995 (CRF 2 ) raised uncertainty as to the roles of each subtype in mediating the actions of CRF (Lovenberg et al. 1995) , including vis-à-vis the depressed neural substrate hypothesized to be common to major depression and drug dependence (Macey et al. 2000) .
In this context, there was much interest in determining the role of each CRF receptor subtype (CRF 1 , CRF 2 ) in mediating dysphoria and, by inference, the anti-dysphoria therapeutic potential of subtype-selective CRF receptor antagonists (Zorrilla et al. 2002; Henry et al. 2006; Cryan et al. 2003b ). In one project, Dr. Markou organized a collaboration between colleagues at The Scripps Research Institute and a pharmaceutical partner at Novartis, Basel, to determine whether antalarmin, a recently identified, first-generation, small-molecule CRF 1 antagonist (see Fig. 1 ), had anxiolytic-like activity in the rat. The findings were among the first to show that selective CRF 1 antagonists reduced naturally occurring anxiety-like behavior (Zorrilla et al. 2002) , joining reports that a structurally related CRF 1 antagonist, CP-154,526, had antidepressant-and anxiolytic-like activities in rodent models (Mansbach et al. 1997; Kehne et al. 2000) .
In the intervening 15 years, an enormity of medicinal chemistry, preclinical testing, and clinical trials concerning CRF 1 antagonists has been performed. Unfortunately, since initial promising results of an open-label phase IIa trial of the CRF 1 antagonist R121919 for the treatment of major depression reported in 2000 (Zobel et al. 2000 ; see Fig. 1 ), a series of disappointing clinical failures have followed. Table 1 summarizes the many drug-like, small molecule CRF 1 antagonists that have failed to successfully complete double-blind, placebo-controlled trials for a wide range of stress-related psychiatric disorders. We and others have reviewed details of these trials previously (Zorrilla et al. 2013; Shaham and De Wit 2016; Sanders and Nemeroff 2016) . In light of these setbacks, a recent commentary noted that CRF 1 receptor antagonists, which were considered by many to have some of the strongest preclinical evidence of recent therapeutic candidates for psychiatric disorders, appeared to have been lost in translation from the laboratory to the bedside (Shaham and De Wit 2016) . Here, we analyze, and in some cases revisit (Zorrilla and Koob 2010; Koob and Zorrilla 2012; Zorrilla et al. 2013; Shaham and De Wit 2016) , possible explanations for the negative outcomes, in order to contructively assess the most current state of the field. In the spirit of avoiding translational obstacles, we also review recent (2014 to present) findings in humans and non-human primates, many of which continue to implicate a role for CRF 1 receptors in psychiatric conditions.
Performance in animal models
Given the perception that CRF 1 antagonists performed well in preclinical models but have performed poorly in the clinic, one might prematurely conclude that existing preclinical models are invalid predictors of clinical efficacy in psychiatric disorders (see also Hyman 2012) . This alarmist interpretation is not well supported. In the alcohol research literature, for example, Shaham and De Wit (2016) noted that other drugs that were effective in animal models of stress-induced reinstatement (e.g., alpha-2 adrenoceptor agonists such as clonidine and lofexidine) were translated to showing efficacy against stress-induced drug craving in human laboratory studies (Mantsch et al. 2016; Sinha et al. 2011 Sweetser et al. 2009 acamprosate and the opioid receptor antagonists naltrexone and nalmefene reduce operant oral ethanol selfadministration in rats under a variety of conditions (Rassnick et al. 1992; Heyser et al. 1998 Heyser et al. , 2003 Sabino et al. 2006; Ji et al. 2008; Gilpin et al. 2008; Walker and Koob 2008) and, analogously, show some efficacy to mitigate alcohol use disorders (see Stevenson et al. 2015; Keating 2013; Rösner et al. 2010; Plosker 2015 ; but see Palpacuer et al. 2015) . Gabapentin reduced both the anxiogenic-like behavior and the increased ethanol self-administration observed in withdrawn, ethanol-dependent rats, but not non-dependent rats (Roberto et al. 2008; Besheer et al. 2016; Watson et al. 1997) and was found to improve emotional function and reduce insomnia and alcohol use in abstinent alcoholics (Bonnet et al. 2007; Malcolm et al. 2007; Brower et al. 2008; Myrick et al. 2009; Mason et al. 2014) . Most recently, the glucocorticoid receptor antagonist mifepristone, which, like CRF 1 antagonists, more efficaciously reduces ethanol intake in dependent rodents during abstinence than in non-dependent rodents (Yang et al. 2008; Simms et al. 2012; Vendruscolo et al. 2012 Vendruscolo et al. , 2015 , was found to reduce alcohol-cued craving in the laboratory as well as naturalistic measures of alcohol use in a double-blind, placebo-controlled study of 56 alcoholdependent human subjects (NCT01548417; Vendruscolo et al. 2015) . Thus, the preclinical models do show predictive sensitivity to detect effective treatments. On the other hand, Haller et al. (2013) have pointed out that, like CRF 1 antagonists, 40% of compounds that showed activity in so-called Bclassical^or Bpopular^animal models of anxiety-like behavior (which are used in~90% of anxiety studies) ultimately failed to show therapeutic activity in humans (Haller et al. 2013) . Accordingly, many neurokinin, cholecystokinin, and 5-hydroxytryptamine type 3 receptor antagonists that showed activity in these preclinical models and were developed contemporaneously with CRF 1 receptor antagonists also were then found to be ineffective to treat anxiety disorders. Thus, even when preclinical models show predictive sensitivity to detect therapeutic compounds (i.e.,~60% of compounds that advanced to human trials based on promising results in anxiety models did ultimately show efficacy), they may have suboptimal specificity. Identical issues hamper preclinical models of antidepressant activity. Solutions to improve not only the sensitivity but also specificity of preclinical anxiety and depression models have been proposed and apply similarly to all psychiatric domains in which CRF 1 antagonists have yet to show clinical efficacy (Haller et al. 2013; Griebel and Holmes 2013; Stewart et al. 2015; Belzung 2014) .
The concept of predictive validity in the literature currently is often used to refer to whether an effective treatment is detected by a model. In reality, however, predictive validity refers to whether a model distinguishes effective vs. ineffective treatments, which jointly reflects the identification of true positives and true negatives in a summary measure of accuracy.
Analogous to how positive and negative predictive values jointly determine the accuracy of diagnostic tests in receiver operating-characteristic (ROC) analyses, both sensitivity and specificity must be considered to determine the predictive validity of animal models. From a screening perspective, the joint use of an animal model with high predictive sensitivity with another having high predictive specificity may yield better outcomes than current screening approaches that focus more on predictive sensitivity (see Abruzzo et al. 2015 for analogous approaches with diagnostic tests). The suboptimal specificity of commonly used models of depression and anxiety disorders may reflect an incomplete implementation of the pathognomonic constructs and pathophysiological bases of these disorders, in contrast with more recently developed models for alcohol use disorder.
Another consideration is the reality that CRF 1 antagonists did not show activity in some models or conditions under which some clinically efficacious treatments do. For example, CRF 1 antagonists did not reduce substance-or cue-induced reinstatement of substance seeking in animal models, so it is unsurprising that they did not reduce alcohol cue-induced craving in human laboratory studies Kwako et al. 2015) . Similarly, CRF 1 antagonists did not reduce and even exacerbated fear-potentiated acoustic startle responses in rat models (Walker et al. 2009 ). Accordingly, the CRF 1 antagonist GSK561679 ultimately increased fearpotentiated acoustic startle reactivity in 31 healthy women (Grillon et al. 2015) . Thus, for a few endpoints, the negative clinical results may actually translate from the preclinical findings.
Along the same lines, whereas several clinically effective treatments like naltrexone, nalmefene, and acamprosate reduce alcohol self-administration in rat models of nondependent alcohol self-administration, including rats genetically selected for high alcohol preference and outbred rats receiving alcohol under intermittent schedules of alcohol access (Rassnick et al. 1992; Heyser et al. 1998 Heyser et al. , 2003 Sabino et al. 2006; Ji et al. 2008; Gilpin et al. 2008; Walker and Koob 2008) , CRF 1 antagonists frequently did not (Sabino et al. 2006 (Sabino et al. , 2013 Gilpin et al. 2008 ). Rather, they differentially or more strongly showed effects in rats that had been made dependent on alcohol due to chronic intermittent exposure (but see also some positive findings in non-dependent rat models (Simms et al. 2014; Cippitelli et al. 2012 ) and mouse models (Lowery et al. 2010 Sparta et al. 2009 Sparta et al. , 2008 ) models. Similarly, unlike benzodiazepines, CRF 1 antagonists did not typically show activity under baseline conditions in most models of anxiety-like behavior, including the elevated plus maze (see Zorrilla and Koob 2004) . Likewise, unlike tricyclic antidepressants and noradrenergic or serotonergic reuptake inhibitors, CRF 1 antagonists did not consistently show activity under baseline conditions in rodent forced swim tests and several other models that have been used to screen for antidepressant-like compounds. Rather, they required environmental, pharmacological, or genetic manipulation to induce a stress-like phenotype during testing (or, for some antidepressant-predictive models, did not show activity even under those conditions; see Zorrilla and Koob 2010) . One skeptical interpretation of these results might have been that, even though the forced swim test is subject to false positive results (specificity issue, low positive predictive value), perhaps the predictive value of a negative result in the model is high (sensitivity issue, high negative predictive value). CRF 1 antagonists might thereby have not been expected to show antidepressant-like activity. Instead, the collective findings were regarded as being conceptually appealing and heralded as evidence that pathological substance use and dysphoria are associated with the recruitment of otherwise quiescent CRF-CRF 1 synaptic transmission, a hypothesis also supported by molecular and electrophysiological studies in preclinical models.
Revisionist hypotheses and their implications
In light of the negative findings to date in clinical studies, revised hypotheses concerning the manner of CRF-CRF 1 recruitment needed for therapeutic activity have been offered. For example, CRF 1 antagonists were proposed to be effective in Bspecific psychiatric disorders in which stress was a dynamic rather than chronic condition^(to include, for example, PTSD, panic, and addiction disorders and exclude major depression and generalized anxiety disorder; Koob and Zorrilla 2012) or in which central CRF overactivation was explicitly present. Neither of these hypotheses has been fully evaluated yet, but they raise several testable predictions.
One interpretation of the dynamic revision is not only that only certain types of stress-related disorders may be treatable by CRF 1 antagonists but also that a given patient may be more sensitive to CRF 1 antagonist treatment earlier in the course of their disorder (before CRF activation has become chronic). The dynamic revision also suggests that sensitivity to CRF 1 antagonists might decrease with greater chronicity in preclinical models and that repeated CRF 1 activation (as in chronic stress) may lead to plasticity within or downstream of CRF 1 receptor signaling that comes to perpetuate the maladaptive behavior comparatively less dependent on subsequent acute CRF 1 agonist stimulation. Possible mechanisms for such plasticity have been described, including kindling, priming, heterologous sensitization, altered G protein coupling, altered splicing, and long-term potentiation (Lee et al. 2008; Ray et al. 2011; Sajdyk et al. 1999; Rainnie et al. 2004; Narla et al. 2016; Zmijewski and Slominski 2010; Dunn et al. 2016; Magalhaes et al. 2010; Brunson et al. 1998; Rajbhandari et al. 2015; Huang et al. 2010; Krishnan et al. 2010 ). It may be that patients present for treatment later in their disease course, after more such plasticity has occurred, as compared to preclinical models, which are designed for expeditious testing. Finally, the dynamic revision suggests that patients may be more responsive to CRF 1 antagonists during particular circumstances or stages of their disorder during which stress responses play a greater role in driving symptoms. In support of the final proposition, oral CRF 1 antagonist emicerfont administration (and not placebo) selectively reduced the bloodoxygen-level-dependent functional magnetic resonance imaging (BOLD fMRI) signal in the hypothalamus, amygdala, hippocampus, insula, anterior cingulate, and orbitomedial prefrontal cortices in patients with irritable bowel disease who were actively experiencing anxiety in anticipation of visceral pain (Hubbard et al. 2011) . Similarly, the CRF 1 antagonist R317573/JNJ19567470/ CRA5626 decreased regional glucose utilization in the amygdala (Schmidt et al. 2010 ) and anxiety responses to 7.5% acute CO 2 inhalation challenge in a double-blind, placebo-controlled trial with healthy men (Bailey et al. 2011) .
Relatedly, the CRF overactivation revision suggests that CRF 1 antagonists may be effective in patients who show high activity in CRF-CRF 1 systems (on either a trait or state basis). This could be probed by biochemical (e.g., high cerebrospinal fluid CRF), neuroimaging (e.g., altered CRF 1 receptor availability), endophenotypic (e.g., increased rapid eye movement [REM] sleep/pressure signs of high CRF drive; see also , or genetic (e.g., functional single nucleotide polymorphisms [SNPs] in CRF system molecules; Holsboer and Ising 2010; Zorrilla et al. 2013; Sanders and Nemeroff 2016; Treutlein et al. 2006; Barr et al. 2008; Nelson et al. 2010; Heilig et al. 2011) means. Significant limitations of the often cited initial clinical study that obtained promising results with R121919 in patients with major depression (Zobel et al. 2000) include that it was small, not double-blind, and did not show a significant cross-sectional difference between subjects treated with the high-vs. low-escalating dose schedule. With regard to potential markers of treatment response, however, a reanalysis of the study found that patients with increased REM sleep density during the first half of the baseline night showed a greater reduction of Hamilton-Depression scores with highdose R121919 treatment than those that did not. Low-dose R121919 treatment was ineffective in all groups (Held et al. 2004 ). On the other hand, several SNPs for CRF 1 and CRFbinding protein (CRF-BP) did not predict treatment response to pexacerfont in patients with generalized anxiety disorder (Coric et al. 2010) . Thus, validating therapeutically prognostic markers of CRF-CRF 1 activation in double-blind, placebo-controlled studies may be a key.
Targeting and validating drug action in humans
Clinical trial failures alternatively might reflect the inadequacy of prioritized drug candidates to quiet central CRF 1 signaling in humans. Indeed, early CRF 1 antagonists had unacceptably high lipophilicities and other physiochemical properties not characteristic of successful CNS drugs, leading to high toxicity potential and poor bioavailability (see Zorrilla and Koob 2010) . Some compounds were suggested to yield negative results because they had lower CRF 1 affinity than R121919 (e.g., CP-316,311; Holsboer and Ising 2010). More recently, it was proposed that a long duration of receptor residency may be a key for efficacy (Fleck et al. 2012; Zorrilla et al. 2013) , because R121919 had slower receptor dissociation rates than compounds that had failed clinically. In support of the importance of this property for antagonist action in vivo, verucerfont (NBI-77860; see Fig. 1 ), a high-affinity, drug-like (Zorrilla and Koob 2010) , CRF 1 antagonist with long receptor residence, was found, like R121919, and unlike the fasterdissociating compounds pexacerfont and CP-316,311, to reduce circulating adrenocorticotropic hormone (ACTH) in adrenalectomized rats. In anxious individuals with alcohol use disorder, verucerfont also reduced ACTH and cortisol responses to dexamethasone/CRF challenge and blunted right amygdala fMRI activation responses to fearful faces, activities that had not been seen for the faster-dissociating pexacerfont Kwako et al. 2015) . These findings validate the drug's pharmacological action. Also, as expected, verucerfont did not reduce alcohol cue-induced craving or anxiety, negative findings consistent with the lack of action of CRF 1 antagonists in animal models of cue-induced craving. Unexpectedly, however, verucerfont still did not reduce alcohol craving or anxiety induced by public speaking or by stressrelated guided imagery; rather, it worsened anxiety associated with the new Trier social stress test of public speaking . Thus, although the verucerfont trial was negative, the confirmation that receptor residence, a previously underappreciated property, was a key for pharmacological action, supports the possibility that not all mechanisms critical for achieving desired CRF 1 silencing in humans have been identified.
To the degree that the biology of human vs. rodent CRF 1 receptors differ (or that of several molecular partners that influence CRF 1 signaling; Dunn et al. 2016; Bonfiglio et al. 2013; Bangasser et al. 2010; Walther et al. 2015) , cryptic species differences also may be impeding therapeutic silencing of CRF 1 receptors in humans. Furthermore, selective CRF 1 antagonists that have been tested to date have no activity at CRF 2 receptors or the CRF-BP. The CRF 2 subtype in rodents has often been regarded as having a net null or perhaps even anxiolytic-like action, but as Dr. Markou and others showed, stimulation of CRF 2 receptors in the lateral septum is anxiogenic in rodents (Bakshi et al. 2007; Henry et al. 2006; Anthony et al. 2014) . Furthermore, in contrast to rodents, which mainly express only CRF 1 receptors in the central nucleus of the amygdala (CeA; Van Pett et al. 2000) , primates also express substantial numbers of CRF 2 receptors of unknown behavioral significance in the CeA (Sanchez et al. 1999 ). Third, humans, but not rodents, possess a unique CRF 2 gamma subtype (Kostich et al. 1998 ). Finally, CRF 2 receptors interact with the CRF-BP to produce actions independent from CRF 1 Ungless et al. 2003; Slater et al. 2016a, b; Milan-Lobo et al. 2009 ).
In this context, the CRF-BP initially had been regarded as serving an inhibitory role in the CRF system, but it has increasingly been recognized to have other modulatory roles in the brain (Westphal and Seasholtz 2006) . Indeed, the CRF-BP has recently received attention as a potential target for its role in alcohol use disorder (Haass-Koffler et al. 2016; Ketchesin et al. 2016 ) and, particularly, its role in the escalation of alcohol drinking may involve an interaction with CRF 2 receptors (Albrechet-Souza et al. 2015; Quadros et al. 2016) . Receptor activity-modifying proteins (RAMPs) are other molecules that interact directly with the CRF system, as RAMP2 binds CRF 1 and increases its surface expression and signaling sensitivity (Wootten et al. 2013 ). However, CRF 1 antagonists to date likewise have not explicitly considered CRF 1 -RAMP2 complexes.
Thus, perhaps small molecules that (1) act as non-selective antagonists at both CRF subtypes, (2) exhibit inverse agonist activity, or (3) also modulate activities of other CRF system molecules, such as CRF-BP or RAMP2 (Wootten et al. 2013; Weston et al. 2016; Gingell et al. 2016) , would have greater therapeutic activity than the many selective CRF 1 neutral antagonists tested to date. Similarly, the structural manner of binding the receptor may be important; perhaps small molecules that bind differentially to certain residues of the atypical allosteric binding site (e.g., compare MTIP vs. CP-376395; Xu et al. 2015) may slow the antagonist's escape kinetics (Bai et al. 2014) or direct its anti-signaling pathway bias (Suen et al. 2014; Zhang et al. 2016 ). Alternatively, a small molecule that binds to the orthosteric (agonist) binding site, rather than to the atypical, deep allosteric binding site that is bound by all clinically evaluated CRF 1 antagonists to date (see Zorrilla and Koob 2010; Hollenstein et al. 2013; Hausch 2013 ) may yield different pharmacological effects. Finally, there are different degrees of inactivity in terms of receptor confirmation, and a recent study showed that a cooperative, double-antagonist approach (one at orthosteric site and one at allosteric site) led to the most inactive state for CC chemokine receptor 2, another G protein-coupled receptor (Zheng et al. 2016; Miao and McCammon 2016) .
The unavailability of a CRF 1 radiotracer for positron emission tomography/single-photon emission computed tomography (PET/SPECT) imaging to confirm adequate receptor occupancy in humans, despite continuing efforts to obtain one that exhibits specific binding in vivo (Stehouwer et al. 2015a, b; Lodge et al. 2014 ) as well as the uncertain density of CRF 1 receptors in the human brain vs. other species (see discussion in Lodge et al. 2014 ) also may be leading to suboptimal prioritization of drug candidates and dosing. A surrogate, non-PET biomarker approach used to predict central receptor occupancy found that even with highly estimated (~90%) occupancy, verucerfont still did not produce a therapeutic action. The development of CRF 1 PET/SPECT radioligands could further validate and refine such surrogate approaches for estimating receptor occupancy.
Recent genetic and molecular findings in humans
In addition to results already cited, several genetic and molecular findings since 2014 in humans and non-human primates continue to implicate CRF-CRF 1 systems in emotional dysfunction, addiction, or stress-related phenotypes (see also Zorrilla et al. 2013 , for review of earlier studies of CRF system SNPs in addiction).
As prelude, major limitations of the genetic variant studies to date are that many of them have not been replicated and, for most, their molecular effect, if any, on the CRF 1 system (as opposed to a putative surrogate marker of CRF 1 system activity) is unknown. Additionally, in general, individual genetic variants are associated with a low percentage of psychiatric disease prevalence. Furthermore, with only a few recent exceptions (see Clarke et al. 2014; Crist et al. 2016 Crist et al. , 2013 Heinzerling et al. 2016) , genetic variants have not yet reliably and reproducibly predicted treatment response in psychiatric diseases (Jones and Comer 2015; Berrettini 2016; Oedegaard et al. 2016) . A molecular, and not only phenotype-based, understanding of a variant's functional effect (if any) may ultimately be needed to understand its prognostic relation to CRF 1 antagonist treatment response.
Major depression
With respect to major depression, the CRHR1 SNPs rs7209436, rs110402, and rs242924 previously had been associated with peak cortisol responses to the Trier social stress test in healthy adults (Mahon et al. 2013) . Recently, it was reported that a TATGA haplotype combination that includes the above three polymorphic loci (rs17689966, rs173365, rs7209436, rs110402, and rs242924) increased the risk of major depression by 68% in a community-based study in southern Spain (Ching-López et al. 2015) . Furthermore, the T allele at CRHR1 rs242941, which forms part of a haplotype that previously had been linked to major depression and antidepressant response (Liu et al. 2006 (Liu et al. , 2007 Licinio et al. 2004) , was linked to a family history of mental illness (Tan et al. 2015) . Smoller (2016) recently reviewed genome-wide association studies that implicate CRHR1 genotype X early childhood maltreatment environmental interactions for major depression risk. Finally, an A-deletion-A CRHR1 haplotype (rs77032924, rs3832590, rs6159) was associated with a trend for poorer response to treatment with mirtazapine or escitalopram in patients with major depression not experiencing stressful life events, perhaps suggesting a role for this haplotype in driving CRF-mediated intrinsic dysphoria that is resistant to non-CRFergic intervention (Chang et al. 2015) .
Suicidality
CRF-CRF 1 systems also were linked to suicidality, with approximately twofold increased CRF messenger RNA (mRNA) in the anterior cingulate of depressed patients who committed suicide as opposed to those who died from natural causes (Zhao et al. 2015) . The C allele at the Crhr1 rs878886 locus was overrepresented in suicide attempters from both Russian and Tatar ethnicity samples (Khalilova et al. 2014 ). In addition, CRHR1 loci that mitigated (rs2664008) or tended to potentiate (rs1724425, rs1526123, rs6503447, rs11655764) suicide risk were identified in a case-control study of individuals with bipolar disorder, the former especially buffering the effects of early childhood abuse (Breen et al. 2015) .
Anxiety disorders
With respect to anxiety disorders, a recent case-control study found that the minor (A) allele of CRHR1 rs17689918, and relatedly, a CGTGA haplotype (rs7209436, rs4458044, rs12936181, rs3785877, rs17689918) increased the risk of panic disorder selectively in women. Unexpectedly, postmortem studies showed that this risk allele was associated with decreased CRF 1 mRNA in the human forebrain and amygdala. Neuroimaging studies found that A allele carriers showed a pattern of altered fMRI signal in the prefrontal cortex and amygdala that was interpreted to reflect overgeneralization of fear conditioning and underprocessing of safety signals; A allele carriers also showed less flight and more anxious apprehension behaviors in response to fear-provoking stimuli. While the results implicate CRF 1 in anxious processing in panic disorder, they do so in an unexpected direction and also indicate that pharmacogenetic selection of patients in which CRF 1 receptors play a role may need to be considered in a sexspecific manner (Weber et al. 2016 ). An additional concern here as well is if a patient has fewer CRF 1 receptors, then they have less available drug targets.
In apparent opposition to the findings in people with panic disorder, Kalin and colleagues observed that viral vectormediated overexpression of CRF in the CeA of young rhesus monkeys led to increased anxious temperament (freezing, cooing, and cortisol reactivity in response to a human intruder). The increase in anxious temperament correlated directly with increased fluorodeoxyglucose metabolism (by PET) and fMRI functional connectivity within a circuit that included the dorsal amygdala, orbital proisocortex/anterior insula, and hippocampus (Kalin et al. 2016) .
Addiction
With respect to addiction, the CRHBP rs1875999 locus was associated with a risk of both cocaine and heroin addiction in African Americans in a study of heroin addicts (n = 314), cocaine addicts (n = 281), and healthy controls (n = 208) (Levran et al. 2014) . SNPs in the CRHBP (10-kD) fragment, rs10055255, rs10062367, and rs7728378, were each shown to be associated with an increased risk of alcohol drinking and/or anxiety in patients with alcohol use disorder (Haass-Koffler et al. 2016) .
Irritable bowel syndrome
Several recent human studies further implicated CRF-CRF 1 activity in irritable bowel syndrome (IBS), a heterogeneous diagnosis that involves abdominal pain, altered bowel habits, gastrointestinal (GI) symptom-specific anxiety, and altered, stress-sensitive brain-gut interactions, often in association with comorbid anxiety or mood disorders. First, men with IBS showed increased sensitivity to intravenous CRF infusion, with greater right amygdala activation (by H 2 15 O-PET) and peripheral norepinephrine secretion than in healthy controls ). Second, the major alleles of CRHR1 rs110402, rs242924, and rs720943 (all C) were associated with an increased risk of IBS and, within IBS patients, increased GI symptom-related anxiety. Unexpectedly, IBS patients with the same risk alleles showed reduced acoustic startle responses vs. healthy controls, whereas those with the minor alleles did not, indicating a complex influence of the CRHR1 SNPs on different symptoms of anxiety per diagnostic group (Orand et al. 2016) . Finally, a separate study of young Japanese individuals observed that the CRHR1 rs10474485 locus was associated with increased psychometric scores for depression, perceived stress, or state/trait anxiety in IBS patients with diarrhea or mixed symptoms, with the CRHR1 variant more predictive of differences in emotional scales in women than in men . Two CRHR2 variants, rs4722999 and rs3779250, have also been associated with the genotype frequency of IBS, and the distribution of the major allele was significantly different in IBS patients compared to controls (Komuro et al. 2016 ).
Other emotion-related phenotypes
A recent neuroimaging study of school-age children was performed, involving a genetic profile score that predicts HPAaxis reactivity, wherein five of the 10 SNPs used to calculate the genetic profile score involved CRHR1 loci (rs4792887, rs110402, rs242941, rs242939, and rs1876828). Higher genetic profile scores were found to predict greater amygdala and hippocampal fMRI activational responses to facial stimuli in pubertal, but not non-pubertal, children. In pubertal children, differential activation to fearful faces was seen in girls and to neutral faces in boys (Pagliaccio et al. 2015) . The results again are consistent with the possibility of sex differences in the functional significance of CRF 1 genetic variants in a manner that depends upon developmental milestones associated with puberty. Indeed, gonadal hormones influence the regulation of CRF system molecules in both male and female rats in a puberty-relevant manner (Bangasser and Valentino 2012; Gomez et al. 2004) . Furthermore, Valentino and colleagues have described sex differences in the signaling pathway bias of CRF 1 receptors in rodents (Valentino et al. 2013a, b) , a mechanistic difference that may be relevant to some of the reviewed sex differences in the functional impact of CRHR1 genetic variants.
A separate imaging study at the Duke Neurogenetics Center examined the widely studied CRHR1 locus rs110402, which, as reviewed above, has been associated with increased HPA-axis reactivity, in interaction with a locus relevant to a gene-encoding fatty acid amide hydrolase, an enzyme that degrades the endocannabinoid anandamide. Individuals with a genetic background of increased CRF 1 signaling (A homozygotes) in combination with increased anandamide inhibitory tone (FAAH 385A carriers) showed decreased habituation of the BOLD fMRI response of the basolateral amygdala during emotional facial processing. The blunted amygdala habituation, in turn, was associated with an increased risk of an anxiety disorder (Demers et al. 2016) . Interestingly, the rs110402 locus also was associated recently with a premature decline in working memory, but not other measures of neuropsychological function, across the life-span. The finding has been interpreted to reflect a chronic deleterious influence of stress reactivity (Grimm et al. 2015) .
Finally, the GGA haplotype at polymorphic loci of the CRHR1 gene (rs4458044, rs242924, and rs1768996) was associated with aggressive behavior towards others as determined in a Han Chinese sample of violent criminals (Chen et al. 2014 ).
Summary
Variants of the CRHR1 and CRHBP genes continue to be associated with the diagnoses, phenomenology, and/or nonCRFergic treatment response of major depression, suicidality, panic disorder, and IBS. Findings also implicate other stressrelated (endo)phenotypes, including not only HPA-axis reactivity and startle reactivity but also more novel findings, such as altered amygdala habituation or activation during facial processing, premature impairment of working memory, and physical aggression. A new development includes the finding that there may be sex differences or developmental (pubertal) moderation of the predictive relation of some genetic variants and that for some phenotypes (e.g., panic disorder, startle reactivity between IBS patients and controls). Particular CRF 1 variants also appeared to have effects opposite to those anticipated from a simple model of greater CRF 1 activation always having an anxiogenic action. The latter result may reflect that CRF 1 activation in some brain regions may have anxiolyticlike effects, including via a circuit action to inhibit anxiogeniclike effects of CRF 1 activation elsewhere (Sztainberg et al. 2011; Walker et al. 2009 ). These results may also relate to why CRF 1 antagonists even exacerbated anxious or fearful symptomatology in two human studies (Grillon et al. 2015; Schwandt et al. 2016) .
Variants that have been replicated across studies and which, at the least, associate with an endophenotype of CRF 1 activation, such as rs7209436, rs110402, or rs242924, are hypothesized to be more likely to predict better treatment response to CRF 1 antagonists. However, as alluded to previously, important criticisms of these genetic variant studies include that their associated odds ratios, even when significant, have been modest (Levran et al. 2014) , and many genetic variants have unknown molecular effects, if any, on the CRF 1 system. Additionally, many genetic variant studies failed to replicate (Buttenschøn et al. 2016; Ventura-Juncá et al. 2014) or have not yet been replicated. Finally, the finding that variants of CRHBP and CRHR2 have been associated with psychiatric and stress-related disease lends support to the hypothesis that other components of the CRF system may be involved and warrants further exploration of polymorphisms of CRHBP, CRHR2, and/or RAMP2.
Recent promising CRF 1 antagonist trials in humans
Two clinical trials with CRF 1 antagonists reported potentially promising results during 2016. First, in a randomized, double-blind, placebo-controlled study that was stopped by the National Institutes of Health Institutional Review Board for reasons unrelated to adverse drug effects or efficacy (reinterpretation of the Common Rule for human subject protection under HHS, 45 CFR 46A), pexacerfont was found to produce effect sizes consistent with the reduction of food craving and laboratory stress-induced eating in a small sample of healthy individuals with restrained eating. Although statistical significance was not seen, the study was stopped prematurely and thereby only had 30% power to detect the stated effect size of interest; thus, it would be inappropriate to interpret it as a negative result, and the observed effect sizes may inform whether future, appropriately powered studies are warranted. The effect size for pexacerfont's reduction of laboratory stress-induced eating was r = 0.30 (counternull r = 0.55; Rosenthal and Rubin 1994) and for its reduction of craving for sweet foods (brownies and Swedish fish) ranged from r = 0.28 to 0.49 (counternull rs = 0.52-0.79). Furthermore, in bogus taste tests designed to mask the true dependent measure of interest (intake), pexacerfont reduced eating of palatable foods independent of which imagery script was presented before food access (neutral, food cue, stress) with an effect size of r = 0.34 (counternull r = 0.61). Finally, nightly Yale Food Addiction Scale (YFAS) scores were consistently lower in subjects receiving pexacerfont (vs. placebo) beginning the evening after the first loading dose of pexacerfont with an effect size of r = 0.39 (counternull r = 0.68). Because the study was stopped prematurely (n = 11-13/group for laboratory studies and n = 13-17/group for YFAS ratings), only the YFAS result was significant at the p < 0.05 level. However, Bayes factor analysis, a ratio that relates to the relative probability of an effect actually being present vs. the null effect (Goodman 1999) , and counternull analysis, which describes the effect size as likely to be true as the null, indicate a strong positive potential of CRF 1 antagonists to reduce palatable food craving and eating in restrained eaters (Epstein et al. 2016 ) and justify a well-powered clinical trial in this domain. A concern with these results is that the YFAS scores had changed as early as 24-h posttreatment, and the degree of central nervous system exposure obtained at that time is uncertain, leading one to question the CRF 1 antagonist mechanism of action. Still, the preliminary results are in accordance with preclinical studies showing that systemic administration of CRF 1 antagonists reduces overeating of a palatable, high sucrose diet in rats receiving intermittent access to the diet (Cottone et al. 2009 ) and also reduce stress-induced reinstatement of palatable food seeking (Ghitza et al. 2006) . Why the clinical results differ from those obtained for alcohol craving with pexacerfont in anxious alcoholics (Kwako et al. 2015 ) is unclear.
The second promising clinical result involved a phase Ib, single-blind, placebo-controlled, fixed-sequence, single-dose trial of verucerfont (NBI-77860; see Fig. 1 ) for 21-hydroxylase deficiency, the most common cause of congenital adrenal hyperplasia. In 21-hydroxylase deficiency, the cortisol synthetic pathway is impaired, leading to a loss of glucocorticoid negative feedback over the HPA-axis (similar to adrenalectomy) and consequent hypothalamic CRF-driven hypersecretion of ACTH, with accumulation of upstream precursors of cortisol, including 17α-hydroxyprogesterone (17OHP). Because 17OHP cannot be processed to cortisol, it instead is converted along the androgen pathway, leading to clinical manifestations of congenital adrenal hyperplasia. Following CRF 1 antagonist treatment, dose-dependent reductions of ACTH and/or 17OHP were observed in six of eight subjects, with overall mean reductions of 41-43% for ACTH and, at the higher antagonist dose, 27% for 17OHP. Thus, the results validate the reviewed clinical finding with verucerfont ) that CRF 1 antagonists with long receptor residence can reduce CRF-driven chronic overactivation of the HPA-axis and indicate one possible therapeutic indication for this action (Turcu et al. 2016 ). This positive finding also is consistent with the revisionist hypotheses that robust pathophysiological overactivation of CRF signaling is a key for therapeutic potential.
Conclusion
We reviewed a range of issues that may explain why CRF 1 antagonists could be said to have been lost in translation from the bench to the bedside. These include not only potential specificity limitations of the preclinical models themselves but also the reality that, for some predictive endpoints, CRF 1 antagonists produced therapeuticlike results only under certain circumstances (e.g., high stress, withdrawal), unlike some clinically effective compounds that act more generally. In some models, CRF 1 antagonists had null or even exacerbating actions, the latter consistent with analogous findings in gene variant and clinical studies. Recognition of this leads to the revised view that the efficacy of CRF 1 antagonists may be correspondingly circumscribed to particular psychiatric disorders or symptoms, patient subgroups, or circumstances in which the activation of pro-stress-like CRF-CRF 1 circuits is dynamically heightened. We described genetic and nongenetic markers that could be evaluated as markers of such activation towards individualized treatment and obstacles that remain for such approaches (e.g., CRF 1 in vivo radiotracer; molecularly validated, functional SNPs). We also discussed both solved and unresolved issues concerning whether small molecules that have been advanced to the clinic adequately engaged human CRF system molecules in the manner needed to attain therapeutic silencing. We also noted mechanisms by which CRF 1 stimulation-induced plasticity within and downstream of CRF 1 receptors may reduce the need for high ongoing CRF 1 agonist stimulation to perpetuate the maladaptive behavior. Finally, we review promising, recent human trials which suggest that CRF 1 antagonists may have potential to reduce craving for and stress-induced eating of palatable food as well as CRF-driven overactivation of the HPA-axis. One must be cognizant of the significant opportunity cost in continuing to pursue selective CRF 1 antagonists for therapeutic use, but given the increasing understanding in the field, several therapeutic avenues with these or, especially, novel anti-CRF compounds remain underexplored. Thus, while it appears that the therapeutic scope of selective CRF 1 antagonists is narrower than had been hoped when Dr. Markou organized those early studies of antalarmin, much remains to be learned about the shared molecular roles of CRF receptors in the neurobiology of stress, dysphoria, and addictive behavior in humans and the potential individualized role of novel anti-CRF approaches therein.
